39684324|t|Decoding Neurodegeneration: A Review of Molecular Mechanisms and Therapeutic Advances in Alzheimer's, Parkinson's, and ALS.
39684324|a|Neurodegenerative diseases, such as Alzheimer's, Parkinson's, ALS, and Huntington's, remain formidable challenges in medicine, with their relentless progression and limited therapeutic options. These diseases arise from a web of molecular disturbances-misfolded proteins, chronic neuroinflammation, mitochondrial dysfunction, and genetic mutations-that slowly dismantle neuronal integrity. Yet, recent scientific breakthroughs are opening new paths to intervene in these once-intractable conditions. This review synthesizes the latest insights into the underlying molecular dynamics of neurodegeneration, revealing how intertwined pathways drive the course of these diseases. With an eye on the most promising advances, we explore innovative therapies emerging from cutting-edge research: nanotechnology-based drug delivery systems capable of navigating the blood-brain barrier, gene-editing tools like CRISPR designed to correct harmful genetic variants, and stem cell strategies that not only replace lost neurons but foster neuroprotective environments. Pharmacogenomics is reshaping treatment personalization, enabling tailored therapies that align with individual genetic profiles, while molecular diagnostics and biomarkers are ushering in an era of early, precise disease detection. Furthermore, novel perspectives on the gut-brain axis are sparking interest as mounting evidence suggests that microbiome modulation may play a role in reducing neuroinflammatory responses linked to neurodegenerative progression. Taken together, these advances signal a shift toward a comprehensive, personalized approach that could transform neurodegenerative care. By integrating molecular insights and innovative therapeutic techniques, this review offers a forward-looking perspective on a future where treatments aim not just to manage symptoms but to fundamentally alter disease progression, presenting renewed hope for improved patient outcomes.
39684324	9	26	Neurodegeneration	Disease	MESH:D019636
39684324	89	100	Alzheimer's	Disease	MESH:D000544
39684324	102	113	Parkinson's	Disease	MESH:D010300
39684324	119	122	ALS	Disease	MESH:D008113
39684324	124	150	Neurodegenerative diseases	Disease	MESH:D019636
39684324	160	171	Alzheimer's	Disease	MESH:D000544
39684324	173	184	Parkinson's	Disease	MESH:D010300
39684324	186	189	ALS	Disease	MESH:D008113
39684324	195	207	Huntington's	Disease	MESH:D006816
39684324	404	421	neuroinflammation	Disease	MESH:D000090862
39684324	423	448	mitochondrial dysfunction	Disease	MESH:D028361
39684324	710	727	neurodegeneration	Disease	MESH:D019636
39684324	1575	1592	neuroinflammatory	Disease	MESH:D000090862
39684324	2049	2056	patient	Species	9606

